AI assistant
NovoCure Ltd — Director's Dealing 2021
Mar 5, 2021
31949_dirs_2021-03-05_90541b05-9589-4c97-8564-a817119fdb76.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-03-03
Reporting Person: Shah Pritesh (Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-03 | Restricted Share Units | S | 2174 | $150.78 | Disposed | 100644 | Direct |
| 2021-03-04 | Restricted Share Units | S | 2658 | $137.554 | Disposed | 97986 | Direct |
Footnotes
F1: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah.
F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units vested on March 3, 2021. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.